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INTRODUCTION
Epstein-Barr Virus (EBV) infection is associated 
with more than 50% of AIDS-related lymphomas 
(ARLs) and other malignancies such as nasopharyngeal 
carcinoma, up to 400 thousand cases each year as 
estimated by the World Health Organization (WHO) 
[1]. The EBV Latent membrane protein 1 (LMP1) 
is a pleiotropic factor that promotes cell growth and 
transformation in vitro as well as in transgenic mice [2]. 
LMP1 oncogenicity is attributed by its ability to activate 
multiple oncogenic transcription factors, including NFκB 
that interacts with other EBV oncoproteins to form viral 
super-enhancers to regulate expression of a large scale 
of host genes involved in lymphoblastoid B-cell growth 
and survival [3].
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ABSTRACT
LIMD1 (LIM domain-containing protein 1) is considered as a tumor suppressor, 
being deregulated in many cancers to include hematological malignancies; however, 
very little is known about the underlying mechanisms of its deregulation and its roles 
in carcinogenesis. Epstein-Barr Virus (EBV) is associated with a panel of malignancies 
of lymphocytic and epithelial origin. Using high throughput expression profiling, we 
have previously identified LIMD1 as a common marker associated with the oncogenic 
transcription factor IRF4 in EBV-related lymphomas and other hematological 
malignancies.  In this study, we have identified potential conserved IRF4- and NFκB-
binding motifs in the LIMD1 gene promoter, and  both are demonstrated functional by 
promoter-reporter assays. We further show that LIMD1 is partially upregulated by EBV 
latent membrane protein 1 (LMP1) via IRF4 and NFκB in EBV latency. As to its role in 
the setting of EBV latent infection, we show that LIMD1 interacts with TRAF6, a crucial 
mediator of LMP1 signal transduction. Importantly, LIMD1 depletion impairs LMP1 
signaling and functions, potentiates ionomycin-induced DNA damage and apoptosis, 
and inhibits p62-mediated selective autophagy. Taken together, these results show 
that LIMD1 is upregulated in EBV latency and plays an oncogenic role rather than that 
of a tumor suppressor. Our findings have identified LIMD1 as a novel player in EBV 
latency and oncogenesis, and open a novel research avenue, in which LIMD1 and p62 
play crucial roles in linking DNA damage response (DDR), apoptosis, and autophagy 
and their potential interplay during viral oncogenesis.
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The LIM domain-containing protein 1 (LIMD1) is 
a member of the ZYXIN family [4]. Like the oncogenic 
transcription factor interferon regulatory factor 4 (IRF4), 
overexpression of LIMD1 is a hallmark of ABC subtype 
of diffuse large B cell lymphoma (DLBCL) [5]. LIMD1 is 
involved in the assembly of numerous protein complexes 
by acting as an adaptor protein that interacts with various 
proteins such as Rb [6], TRAF6 [7], p62/SQSTM1 [8], 
VHL and PHD [9, 10], and LATS and WW45 [11], 
and participates in myriad cellular processes including 
cell fate determination, cytoskeletal organization, 
osteoclastogenesis [8], repression of gene transcription, 
cell-cell adhesion, cell differentiation, proliferation and 
migration. Interaction of LIMD1 with TRAF6 enhances 
the ability of TRAF6 to activate AP1 and negatively 
regulates the canonical Wnt receptor signaling pathway 
in osteoblasts [7], and interaction with p65 negatively 
regulates NFκB activity in human non-small cell lung 
cancer cells [12]. Our previous study has shown that 
LIMD1 and IRF4 expression levels positively correlate 
in different hematological malignancies, including EBV-
associated lymphomas [13].  However, the mechanisms 
underlying its regulation and its role in the setting of EBV 
infection remain uninvestigated.
DNA damage is directly linked to a large range of 
human diseases, including aging and cancer [14–16], and 
usually has severe effects on the cell—triggering cell-cycle 
arrest, cell death or tumorigenesis. Reactive oxygen species 
(ROS), which can be produced by diverse conditions of 
stress such as chronic viral infection and cancer hypoxia 
[17, 18], are one of the major causes of DNA damage 
[19]. Most cancers, if not all, harbor deficient DNA repair 
mechanisms, resulting in increased genomic instability 
and less capacity to respond to DNA damages; therefore 
they heavily rely on alternative DNA repair mechanisms 
for survival [14]. Deficiency in DNA repair mechanisms 
also results in resistance to conventional chemotherapeutic 
agents in cancer cells [20, 21], in which DNA damage-
induced autophagy plays a cryoprotective role [22, 23].  
An increasing body of evidence indicates that 
autophagy and DNA damage closely crosstalk, in which 
the selective autophagy adaptor p62 (known as SQSTM1/
Sequestosome-1) plays a key role [24–27]. As a part of 
the DNA damage response (DDR), autophagy promotes 
DNA damage repair by targeting DDR-related proteins 
including p62 for degradation, contributing to the 
maintenance of genomic stability in aging and cancer [22, 
27]. Many cancer cells have high apoptotic thresholds, 
so autophagy serves as a survival mechanism that allows 
these cancer cells to escape apoptotic or necrotic death 
in response to metabolic crisis. Thus, the heavy reliance 
of many cancer cells on autophagy for survival suggests 
inhibiting autophagy in these cells may be a promising 
therapeutic target [23]. 
In this study, we show evidence that LIMD1 is 
upregulated by LMP1 via NFκB and IRF4 axes in EBV 
latency. We further show that LIMD1 is required for 
LMP1 signal transduction and function. More importantly, 
LIMD1 depletion potentiates ionomycin-induced DNA 
damage, and impairs p62-mediated selective autophagy.
RESULTS
IRF4, NFκB, and LMP1 transactivate the 
LIMD1 gene promoter
We have previously shown that LIMD1 expression 
correlates with IRF4 in hematological malignancies [13], 
suggesting that LIMD1 may be transcriptionally regulated 
by IRF4. One of the IRF4 consensus binding site is  ETS/
ISRE-consensus element (EICE), which has the consensus 
sequence 5-GGAANNGAAA-3 fusing the ETS-binding 
motif (5-GGAA-3) with the IRF4-binding motif 
(5-AANNGAAA-3) [28]. To investigate this possibility 
that IRF4 regulates LIMD1 transcription, we analyzed its 
promoter region, and identified potential EICE and NFκB-
binding sites (Figure 1A), in addition to the known Pu.1-
binding site [29]. Promoter-reporter assay results further 
showed that IRF4, NFκB or LMP1 alone can activate the 
human LIMD1 promoter, but IRF7 had no significant 
effect on it (Figure 1B). To confirm the two potential sites 
are functional, we created a panel of point mutants in these 
sites that were then subjected to promoter-reporter assays 
(Figure 1A). The results show that mutation of either of 
these two sites impairs the LIMD1 promoter activity, and 
mutation of both disables LMP1-stimulated promoter 
activity (Figure 1C). 
We also evaluated the potential cooperation between 
IRF4 and Pu.1 in transactivating the LIMD1 promoter, with 
the LIMD1 promoter construct mutated in the Pu.1-binding 
site [29]. As shown in Figure 1D, cotransfection of IRF4 
with Pu.1 results in dramatically increased activity than 
IRF4 or Pu.1 alone. EBNA2, an EBV nuclear antigen that 
is another Pu.1-binding partner [30], also transactivate the 
LIMD1 promoter but not the mutant with Pu.1-binding site 
mutated; however, no synergic effect between EBNA2 and 
Pu.1 was detected. These data indicate that IRF4 and Pu.1 
can transactivate the LIMD1 promoter in a synergic manner.
We further performed ChIP assays to assess the 
binding of IRF4 and NFκB with the endogenous LIMD1 
promoter in 293 cells. IRF4-DNA and NFκB-DNA 
complexes were pulled down with the Flag M2 antibody, 
and the recovered DNA fragments were subjected to real-
time PCR amplification for a fragment containing the 
potential EICE and NFκB-binding sites. Results indicate 
that IRF4 and NFκB bind to the LIMD1 promoter in 293 
cells (Figure 1E).
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Figure 1: LMP1, NFκB and IRF4 transactivates LIMD1 gene promoter. (A) A diagram showing the LIMD1 promoter 
construct pGL4.10/LIMD1p(-1990/+50)-Luc2 and its mutants. (B) LMP1, NFκB and IRF4 transactivate the wild type pGL4.10/LIMD1p(-
1990/+50)-Luc2. (C) The putative NFκB- and IRF4-binding sites in the LIMD1 promoter are functional. 293 cells in 24-well plates were 
transfected with 150 ng IRF4, 150 ng p65 plus p50, or 10 ng LMP1, 40 ng pGL4.10/LIMD1p(-1990/+50)-Luc2 or its mutant with the Pu.1-
binding site mutated, and 10 ng Renilla. Dual luciferase assay was performed. The ability of the vector control to activate the promoter 
construct was set to 1. (D) Pu.1 and IRF4 synergically transactivate the LIMD1 promoter. 293 cells in 24-well plates were transfected with 
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In conclusion, our results demonstrate that EBV 
LMP1 transactivates the LIMD1 promoter via IRF4 and 
NFκB signaling axes.
LIMD1 expression is upregulated by IRF4 and 
NFκB downstream of LMP1 signaling
We next evaluated the regulation of LIMD1 
expression by IRF4, NFκB, and LMP1. We have 
previously shown that LIMD1 expression is associated 
with IRF4 in EBV-positive and negative B lymphoma cell 
lines [13]. We further show here that the LIMD1 protein 
level is associated with NFκB activity (as indicated by 
IκBα phosphorylation), in B and T lymphoma cell lines 
(Figure 2A). In EBV-negative B cells and type I latency 
where p-IκBα(S32/36) is not detected, LIMD1 levels are 
low or undetectable; however, in EBV type III latency and 
in MT4 T cell line where p-IκBα(S32/36) is considerable, 
LIMD1 expression is readily detectable (Figure 2A). 
Notably, in P3HR1 cells derived from the parental 
JiJoye cell line but lacking LMP1 expression due to the 
deletion of the EBNA2 gene, LIMD1 is also expressed 
at a considerable level; it is however consistently lower 
than that in the parental cell line JiJoye, indicating that 
mechanisms other than LMP1 signaling may contribute to 
the induction of LIMD1 expression in EBV latency. 
We then assessed LIMD1 expression in several cell 
lines including DG75, BJAB and Akata that stably express 
LMP1 vs. vector control. The data show that stable 
expression of LMP1 elevates LIMD1 protein levels in 
these cell lines (Figure 2B). However, transient expression 
of high level of LMP1 promotes proteasome-mediated 
degradation of LIMD1 (see Figure 4). We then assessed 
the LIMD1 protein levels in IB4 cell line stably expressing 
IRF4 or scramble control short hairpin RNAs (shRNAs) 
that were induced by doxycycline (Dox). The shIRF4 
cloned in pTRIPz and control were used in our previous 
publication [31]. Results show that IRF4 deficiency results 
in a consistent decrease in endogenous LIMD1 protein 
levels in IB4 cells (Figure 2C).  We have further blocked 
endogenous NFκB activity in EBV-positive cell lines with 
type III latency and in HTLV1-positive MT4 cell line 
using the IKKβ-specific inhibitor Bay11-7085 and then 
evaluated LIMD1 protein levels. Results show that NFκB 
blockage inhibits LIMD1 expression (Figure 2D).
We also evaluated LIMD1 regulation at the 
transcriptional level using real-time quantitative PCR, and the 
data indicate that LIMD1 mRNA and protein are consistent in 
their regulation by NFκB and IRF4 in these cell lines under 
normal culture conditions (Figure 2E; Figure 3). 
Taken together, our results demonstrate that LIMD1 
is upregulated by NFκB and IRF4 downstream of LMP1 
signaling pathway.
LIMD1 physically interacts with LMP1 and 
TRAF6 
The upregulation of LIMD1 by LMP1 signaling 
implicates that LIMD1 may play a role in EBV latency 
and oncogenesis. As an adaptor protein, LIMD1 interacts 
with TRAF6, and is a positive regulator of NFκB and AP1 
activation; however, it negatively regulates the canonical 
Wnt receptor signaling pathway in osteoclastogenesis 
[7, 8]. The closest family member, Ajuba, also positively 
regulates IL1-stimulated NFκB activation [32]. Thus, we 
first verifed that endogenous LIMD1 and TRAF6 clearly 
interact in EBV-transformed cells (Figure 4A). We have 
further shown that endogenous LIMD1 interacts with LMP1 
as well (Figure 4B). To define the specificity of LIMD1/
LMP1 interaction, we transiently expressed a panel of 
3XFlag-LMP1 deletion mutants (Figure 4C, upper panel) 
with LIMD1 in 293T cells, and cell lysates were collected 
for immunoprecipitation. Our results show that both LMP1 
CTAR1 and CTAR2 interact with LIMD1, and deletion of 
both ablated its ability to interact with LIMD1 (Figure 4C, 
lower panel). 
Of note, our results consistently show that 
overexpression of the full length of LMP1, LMP1 CTAR1 
or CTAR2 results in significantly lower levels of LIMD1 
protein (Figure 4C, lower panel). This downregulation 
occurred at the post-translational level since it was 
prevented by treatment of the cells with MG132,  a 26S 
proteosome specific inhibitor (Figure 4C, lower panel). 
Similar effects of MG132 on endogenous LIMD1 proteins 
were observed in EBV+ B cells with high levels of LMP1 
(Figure 4D). These observations imply that high levels of 
LMP1 promote LIMD1 degradation through a proteosome-
dependent pathway. We will further investigate these 
findings and the underlying mechanism, including 
identification of LIMD1 ubiquitination sites responsible for 
its stability regulation, in a separate project.
Together, these results demonstrate that LIMD1 
interacts with both TRAF6 and LMP1 in EBV latency, and 
imply that high levels of LMP1 downregulate LIMD1 at 
the post-translational level. 
150 ng IRF4, 150 ng EBNA2, 150 ng Pu.1 or their combinations, 40 ng pGL4.10/LIMD1p(-1990/+50)-Luc2 or it mutant with the Pu.1-
binding site mutated, and 10 ng Renilla. Dual luciferase assays and data processing were performed as above. (E) 293 cells in 100-mm 
dishes were transfected with Flag-IRF4, Flag-p65+Flag-p50, or vector control, or mock transfected. Cells were then subjected to 
immunoprecipitation with anti-Flag M2 after 48 h, followed by ChIP assays. For each sample, DNA pellets were dissolved in 200 µl ddH2O, 
and 15 µl was used for qPCR using the primers for LIMD1 promoter EICE and NFκB-binding site. DNA-binding activity is represented 
by relative fluorescence units (RFU). Results are the averages ± standard error (SE) of duplicates. Representative results from at least three 
independent experiments are shown.
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LIMD1 is required for LMP1 signal transduction 
and target gene regulation
Since LIMD1 interacts with TRAF6, a crucial 
mediator for LMP1 activation of NFκB and AP1, we next 
evaluated the requirement of LIMD1 for LMP1 signal 
transduction. To this end, we first depleted endogenous 
LIMD1 expression using LIMD1-specific shRNAs. 
As shown in Figure 5A, we achieved high knockdown 
efficiency using two out of six LIMD1 shRNA constructs. 
After selection of the cells with puromycin and induction 
of shRNA expression by Dox, we assessed NFκB and 
AP1 activity by immunoblotting for phosphorylation 
of IκBα and p38. Results show that depletion of LIMD1 
significantly attenuates phosphorylation of both IκBα and 
p38 that requires TRAF6, but did not have detectable effects 
on PTEN and its phosphorylation at S380 downstream 
of LMP1/PI3K. These results indicate that LIMD1 is 
specifically required for LMP1/TRAF6-mediated signal 
transduction.
Figure 2: LIMD1 is upregulated by NFκB and IRF4 in virus-transformed cells. (A) LIMD1 expression is correlated with 
NFκB activity in B and T cell lines. (B) LMP1 induces LIMD1 expression. BJAB and Akata stable cell lines expressing LMP1 or control 
were generated by transfecting with pLXCN/Flag-LMP1 expression and control plasmids and selected with 2 mg/ml G418 for two weeks, 
and then subjected to immunoblotting analysis for LIMD1 protein. LMP1 in DG75 stable cells was induced by 1 µg/ml doxycycline for 
48 h before collection. All cells were treated with 5 µM MG132 for 6 h before collection. (C) Knockdown of IRF4 in IB4 cells decreases 
LIMD1 protein level in EBV-transformed cells. IB4 stable cell lines expressing pTRIPz/shIRF4 or control were induced with 1 µg/ml 
doxycycline, and IRF4 and LIMD1 protein levels were evaluated. (D) Inhibition of NFκB activity decreases LIMD1 protein levels in 
virus-transformed cells. NFκB activity was inhibited with the NFκB-specific inhibitor Bay11-7085 at the concentration of 2.5 µM for 
48 h. (E) IRF4 depletion by IRF-specific shRNA downregulates LIMD1 mRNA expression in JiJoye cells. JiJoye cells stably expressing 
control and IRF4 shRNAs were treated with 1 µg/ml doxycycline to induce shRNA expression for 96 h. Total RNAs were extracted for 
qPCR to quantitate IRF4 and LIMD1 mRNA expression. The average mRNA levels of the duplicates in shControl-expressing cells were 
set to 100%.
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Figure 3: LIMD1 mRNA level is associated with EBV latency and upregulated by LMP1. (A) RNA was extracted from 
indicated different pair of cell lines, and LIMD1 mRNA expression level was evaluated by real-time qPCR. The average mRNA levels of 
the duplicates in SavI, BJAB, P3HR1, and CEM were set to 1.  (B) Cell lines with high endogenous NFκB activity were treated with 2.5 µM 
Bay11-7085 for 48 h. RNA was then extracted for real-time qPCR analysis for LIMD1 expression. The average LIMD1 mRNA levels 
of the duplicates in DMSO-treated cells were set to 100%. The LIMD1 mRNA levels decreased by Bay11-7085 treatment are shown as 
percentage of those with corresponding DMSO controls. Statistical analysis was performed on results from three independent experiments. 
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We next assessed the requirement of LIMD1 
in regulation of LMP1 target gene expression. We 
performed immunoblotting and real-time qPCR for 
selected LMP1 targets, including IRF4, IRF7, and Bcl6 
[33–35]. Our data show that protein levels of IRF4 
and IRF7 are significantly downregulated in LIMD1 
shRNA-expressing cells, compared with control 
shRNA-expressing cells (Figure 5B), and Bcl6 mRNA 
levels are increased (Figure 5C). We also show that 
p62 mRNA is downregulated in LIMD1-deficient cells 
(Figure 5C).
Taken together, these results indicate that LIMD1 is 
required for LMP1 signal transduction and regulation of 
its target genes.
Figure 4: LIMD1 interacts with TRAF6 and LMP1 in EBV latency. (A) IB4 and JiJoye cell lysates were subjected to 
immunoprecipitation with the TRAF6 antibody clone 1H4L2 and then immunoblotting with the LIMD1 antibody clone H-4 (upper), or 
vice versa (bottom). (B) IB4 and JiJoye cell lysates were subjected to immunoprecipitation with the LMP1 antibody clone CS1-4 and 
then immunoblotting with the LIMD1 antibody H-4 (upper), or vice versa (bottom). (C) Upper panel: A diagram of the LMP1 deletion 
mutants for immunoprecipitation. Lower panel: 3XFlag-LMP1 and its mutants were co-transfected with pcDNA3/LIMD1 into 293T 
cells. After 48 h, cells were collected and cell lysates were subjected to immunoprecipitation with the LIMD1 antibody clone H-4, and 
immunoprecipitants were probed with the Flag antibody M2. For MG132 treatment, MG132 was added at a final concentration of 10 µM 
for 6 h before collection. (D) Cells were treated with MG132 at a final concentration of 10 µM for 6 h before collection. Cell lysates were 
subjected for IB with the indicated antibodies. 
Oncotarget6289www.impactjournals.com/oncotarget
Figure 5: LIMD1 is required for LMP1 signal transduction and regulation of target genes. (A) and (B) IB4 cell lines stably 
expressing LIMD1 shRNA #1 and #2 were induced by 1 µg/ml doxycycline for 48 h for LIMD1 shRNA expression, and cell lysates were 
then subjected to immunoblotting for analysis of the LMP1 downstream pathway activity and target gene expression. (C) LIMD1, IRF4, 
p62 and Bcl6 in IB4 stable cell line expressing LIMD1 shRNA #1 were also analyzed at mRNA levels using real-time quantitative PCR. 
The average mRNA levels of the duplicates in shControl-expressing cells were set to 100%.
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LIMD1 depletion potentiates DNA damage-
induced cell death and inhibits autophagy
EBV latent infection causes genomic instability 
through different mechanisms independently mediated 
by EBNA1 and EBNA3C, and LMP1 [36]; among these 
LMP1 inhibits DNA repair in epithelial cells through 
distinct mechanisms, including its ability to inhibit DNA-
PK/AMPK signaling [37], to inhibit PI3K/Akt/FOXO3a 
signaling [38], and to downregulate expression of ATM. 
ATM is a key PI3K-like kinase that phosphorylates 
multiple factors, such as CHK2, 53BP1, BRCA1 and 
H2AX, for double-stranded DNA repair [39].
To further assess the functional role of LIMD1 
in EBV latency, we evaluated DNA damage and cell 
death of IB4 cells stably expressing LIMD1 shRNAs 
in response to ionomycin treatment. Ionomycin is an 
ionophore used in research to raise the intracellular level 
of calcium (Ca2+); intracellular levels of calcium influx 
are essential for ROS production [40], causing DNA 
damage. Our data show that ionomycin treatment induces 
apoptosis in EBV-transformed IB4 cells, as shown by 
Annexin V expression (Figure 6A) and caspase 3 activity 
(Figure 6B), and also strikingly induces DNA damage, as 
evidenced by expression of γH2AX, a hallmark of DNA 
double-strand breaks (Figure 6B). Notably, depletion 
of LIMD1 significantly potentiates ionomycin-induced 
apoptosis (Figure 6A and 6B), and remarkably increases 
DNA damage induced by ionomycin (Figure 6B). Taken 
together, our results demonstrate that LIMD1 depletion 
results in an enhancement in ionomycin-induced apoptosis 
and DNA damage.
Consistent with a previous report [41], our results 
show that ionomycin treatment elevates the protein level of 
p62, which is well known as a selective autophagy adaptor, 
and consequently, induces autophagy, as shown by the 
expression of LC3-II, a hallmark of autophagy (Figure 6B). 
LC3β has two forms, the cytoplasolic form LC3-I and 
the autophagosome membrane-bound form LC3-II; the 
latter is a hallmark of autophagy. However, LC3-II was 
not detected in cells with LIMD1 depletion. p62 itself is 
a target of and is degraded by selective autophagy [42]. 
Correspondingly, p62 is increased at the protein levels in 
cells with LIMD1 depletion as a consequence of impaired 
autophagy (Figure 6B). Our results thus indicate that 
LIMD1 depletion results in attenuation of ionomycin-
induced, p62-mediated selective autophagy.
In contrast to p62, LMP1 protein levels are 
remarkably decreased in cells with autophagy, consistent 
with a previous report that LMP1 is degraded by 
autophagy [43]. Correspondingly, the anti-apoptotic NFκB 
activity, which is stimulated by LMP1, is also impaired 
by ionomycin, in line with its ability to induce apoptosis 
(Figure 6B). The LIMD1 protein level is decreased 
as well, suggesting that LIMD1 is also degraded by 
autophagy, or this decrease is due to transcriptional 
suppression by dampened LMP1/NFκB signaling 
(Figure 6B). Additionally, after LIMD1 depletion, LMP1 
protein levels are generally lower even in the absence of 
autophagy (Figure 6B). This could be explained by our 
above results that LIMD1 depletion blocks LMP1 signal 
transduction, and consequently impairs NFκB activity that 
is involved in LMP1 autoregulation [44]. We obtained 
similar results from JiJoye cells that were derived from a 
BL cancer patient, i.e. LIMD1 depletion results in severer 
DNA damage, diminished autophagy and increased p62 
protein levels (Figure 6C).
In general, autophagy precedes apoptosis, which 
occurs when the protective ability of autophagy is 
overcome by a stimulus such as ionizing radiation or 
chemotherapeutic anticancer agents; in turn, apoptosis 
inhibits autophagy [45–47]. The Bcl2 family plays a key 
role in linking these two processes [48, 49]. To explore 
the mechanism underneath ionomycin induction of p62-
mediated autophagy and the role of LIMD1 in this process, 
we evaluated the expression regulation of selected Bcl2 
family members, including Bim, Noxa, BNIP3, and Bcl-
xL, which have been documented in autophagy [48, 49]. 
The protein level of the pro-apoptotic Bim, but not Noxa, 
is increased after LIMD1 depletion and futher elevated 
by ionomycin treatment (Figure 6D). Bim can inhibit 
autophagy by directly interacting with Beclin 1 [50]. 
Other tested Bcl2 family members did not change at 
protein levels after LIMD1 depletion (data not shown). 
These results suggest that LIMD1 depletion inhibits p62-
mediated autophagy through upregulating Bim expression. 
Taken together, our results indicate that LIMD1 
confers EBV-transformed cells resistance to DNA damage 
and apoptosis, but renders them susceptible to autophagy, 
at minimum through suppressing Bim expression.
DISCUSSION
In this study, we provide solid evidence for the 
regulation of LIMD1 expression by LMP1 through the 
NFκB and IRF4 signaling axes. We further show that 
LIMD1 is required for LMP1 signal transduction and 
functions. Moreover, our results have identified LIMD1 
as a novel player in EBV latency and oncogenesis by 
protecting EBV-transformed cells from DNA damage and 
apoptosis but rendering them susceptible to autophagy 
(Figure 7). 
Our results show that, in P3HR1 cells, which lack 
EBNA2 and LMP1, LIMD1 protein and mRNA are still 
expressed at considerably high levels, implying that 
factors other than EBNA2 and LMP1 in EBV latency 
contribute to LIMD1 upregulation. In fact, in addition 
to EBNA2, EBNA3s are also Pu.1-binding proteins, and 
they may induce LIMD1 expression in cooperation with 
Pu.1, which transactivates the LIMD1 promoter [29]. 
It is also notable that, when LMP1 is overexpressed in 
EBV-negative B cells, it caused downregulation, in lieu 
Oncotarget6291www.impactjournals.com/oncotarget
Figure 6: LIMD1 depletion potentiates ionomycin-induced DNA damage and apoptosis, and impairs autophagy. 
(A) IB4 cell lines stably expressing LIMD1 shRNA #1 and control were treated with ionomycin for 48 h, and apoptosis was analyzed by 
flow cytometry for Annexin V binding. The right graph shows an analysis for a representative experiment with duplicate for each sample 
(mean ± SE). (B–D) IB4 cell lines (B) and (D) and JiJoye cell lines (C) stably expressing LIMD1 shRNA #1 and control were treated with 
ionomycin for 48 h (B) and (D) or time points (C). 2.5 µg/ml and 5.0 µg/ml in (B) and 2.5 mg/ml in (C) and (D). DNA damage, apoptosis, 
and autophagy were evaluated by immunoblotting for related hallmarks: the DNA damage hallmark γH2AX, the autophagy hallmark LC3-
II, and the apoptosis hallmark Caspase 3 activity. Bim and Noxa were also analyzed.
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of upregulation, of LIMD1 expression (data not shown), 
and also downregulation of Bcl2 that is known to be 
upregulated by LMP1 in EBV latency. This parodox can 
be explained by the fact that LMP1 plays dual roles in cell 
fate; high levels of LMP1 induces apoptosis, rather than 
cell transformation [51, 52].
It has been reported that EBNA3A and EBNA3C 
cooperate with IRF4 transcriptional complex to inhibit 
Bim expression, and therefore protect EBV-positive cells 
from DNA damage-induced apoptosis [53, 54]. We show 
here that LIMD1 depletion results in upregulation of Bim, 
consistent with our conclusion that LIMD1 is required 
for LMP1 signal transduction in that LMP1 induces and 
activates IRF4 [55]. It has also been shown that, however, 
ionomycin-induced apoptosis is dependent of neither 
p53 nor Bim in EBV-positive cells [56], but depends 
on another pro-apoptotic Bcl2 family member Noxa 
[53], whose expression was not changed in response to 
ionomycin treatment in our experiments. Nevertheless, it 
is worthy of further investigation to assess the interaction 
between Bim and LIMD1 in EBNA3 inhibition of 
apoptosis in response to different chemotheraputic drugs.
LIMD1 depletion is associated with more severe 
DNA damage in EBV-transformed cells in response to 
Figure 7: A diagram showing the interplay between LIMD1 and LMP1. LMP1 induces LIMD1 expression via NFκB and IRF4 
axes. In turn, LIMD1 participates in LMP1 signal transduction by interacting with TRAF6. LIMD1 protects EBV-transformed cells from 
DNA damage through inducing p62-mediated autophagy that plays a crucial role in DNA repair in cancers, and this function may or may 
not depend on LMP1 signaling in that LIMD1 may be regulated and promotes DNA repair through other LMP1-independent mechanisms. 
LMP1 may induce autophagy through distinct but not fully understood mechanisms, one of which involves p62 that is likely induced by 
LMP1/NFκB. The pathways with broken lines represent several possible LMP1-dependent and -independent mechanisms underlying EBV 
regulation of p62-mediated autophagy, and are under our investigation. ① LIMD1 participates in LMP1 signal transduction to NFκB 
activation and ROS production, both of which induce p62; ② Other EBV factors may indirectly induce p62 expression; for example, 
EBNA1 and EBNA2 produce ROS that is able to induce p62; ③ LIMD1 inhibits expression of Bim that is known to inhibit p62-mediated 
autophagy; ④ p62 interacts with LIMD1 and TRAF6 in a multi-protein complex that facilitates NFκB activation in diverse contexts, and 
this mechanism may also function in LMP1 activation of NFκB; ⑤ LIMD1 may regualte p62-mediated autophagy through other LMP1-
independent strategies.
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ionomycin treatment. This consequence may be attributed 
by two mechanisms.  The first is that LIMD1 depletion 
results in more DNA damage directly. The second is 
that LIMD1 depletion impairs a functional DNA repair 
machinery. Our results show that, in LIMD1-deficient 
cells, p62-mediated selective autophagy in response to 
ionomycin treatment is remarkably dampened. Since p62-
mediated selective autophagy plays a crucial role in DNA 
repair in cancer cells [22, 23, 27], we believe that LIMD1 
protects EBV-transformed cells from DNA damage by 
playing an indispensable role in induction of p62-mediated 
selective autophagy, which serves as a survival mechanism 
by participating in DNA repair in cancer cells that are 
usually deficient in traditional DNA repair mechanisms 
such as non-homologous end jointing (NHEJ) [14, 23].  
We are now investigating potential LMP1-
dependent and independent mechanisms underlying the 
interplay between p62-mediated autophagy and DDR in 
EBV latency. In fact, we show here that LIMD1 depletion 
promotes Bim protein expression, and Bim is known to 
inhibit autophagy [50]. As a second possible mechanism, 
LIMD1 is required for LMP1 signaling, which is known 
to regulate unfolded protein responses and autophagy 
through multiple mechanisms that have not been fully 
disclosed, including its ability to induce autophagy through 
its N-terminal six transmembrane domains and its ability 
to induce ROS that induces autophagy [17, 43, 57–61]. 
Third, p62 is known to be upregulated in response to ROS 
production that is induced individually by three LMP1 
latent proteins, including LMP1, EBNA1, and EBNA2 
[36, 57, 62]. Fourth, it is interesting that p62 interacts 
with LIMD1 in the multi-protein complex LIMD1-p62-
TRAF6-PKCζ that regulates IL1 and RANKL signaling 
[7, 32]. The association between p62 and TRAF6 also 
facilitates NFκB activation in Ras, TNFR, nerve growth 
factor (NGF), and Toll-like receptor (TLR) signaling 
pathways [63–67]. Considering that LMP1 interacts with 
p62 in a high throughput screen [68], it is conceivable that 
both LIMD1 and p62 interact with TRAF6 downstream 
of LMP1 signaling and cooperate to regulate the interplay 
between LMP1-mediated DDR and autophagy.
LIMD1 is deemed a tumor suppressor [6]. It represses 
the anti-oncogenic Hippo pathway by antagonizing YAP1 
phosphorylation [11, 69], and promotes ubiquitination-
mediated HIF1α degradation by interacting with the 
tumor suppressor VHL [9, 10]. It is also downregulated, 
and inhibits NFκB activity and autophagic cell death, in 
human non-small cell lung cancer cells [12]. Surprisingly, 
its expression is positively correlated with expression of 
the oncogene IRF4 in EBV latency, and it is required for 
LMP1 oncogenic functions and its depletion promotes 
DNA damage and apoptosis. It is also overexpressed in 
and is a hallmark of ABC DLBCL [5]. Further, our results 
indicate that LIMD1 is downregulated at transcriptional 
and/or post-translational levels, in cells either with LMP1 
overexpression that induces cell death or in response 
to ionomycin treatment that induces DNA damage and 
apoptosis. Thus, we believe that LIMD1 plays an oncogenic 
role in EBV-associated lymphomas and other hematological 
malignancies, although further verification in animal models 
is required.  The paradox roles of LIMD1 may depend on 
its post-translational modifications; cell-cycle-dependent 
phosphorylation may play a role in its function as a tumor 
suppressor [70]. 
Our intriguing observations open a novel research 
avenue in the field of EBV oncogenesis that involves 
DDR, apoptosis, and autophagy, and their interplay 
mediated by LIMD1 and p62 in EBV oncogenesis, which 
have never been reported. We believe that future in-depth 
mechanistic studies will provide key innovative insights 
into EBV oncogenesis. 
MATERIALS AND METHODS
Constructs, antibodies, and reagents
pGL4.10/LIMD1p(-1990/+50)-Luc2 and its mutant 
with the Pu.1-binding site mutated were described 
previously [29]. 3XFlag-tagged LMP1 and mutants, and 
other expression constructs were described in our recent 
paper [55]. Deletion and point mutants were generated 
by subcloning or site-directed mutation (Stratagene), and 
verified by sequencing. LIMD1 cDNA was amplified from 
IB4 cell line with the primer pair: forward: 5′-CCGGAA
TTCATGGATAAGTATGACGACCTGG-3′ and reverse: 
5′-GCTCTAGACTAGAAGTGGTGCTGGTGAAGG-3′, 
and cloned into pcDNA3 at EcoRI and XbaI sites and 
verified by sequencing. The set of LIMD1 shRNAs that 
includes 6 LIMD1 shRNAs constructed in the lentiviral 
vector pTRIPz was purchased from Open Biosystems. 
We chose two of them with the highest knockdown 
efficiencies for loss-of-function assays.
LMP1 mouse monoclonal antibody (clone CS1-4) 
was purchased from Dako. IRF4 mouse monoclonal 
antibody (clone MUM1p) and goat polyclonal antibody 
(clone M17), LIMD1 mouse monoclonal antibody 
(clone H4), and p62 mouse monoclonal antibody (D-3) 
were from Santa Cruz for immunoprecipitation and 
immunoblotting. LC3b rabbit polyclonal antibody was 
from Invitrogen. γH2AX(S139) monoclonal antibody was 
from BioLegend. TRAF6 rabbit monoclonal antibody 
(clone 1H4L2) and rabbit polyclonal antibody (clone 
H274) were from ABfinity and Santa Cruz, respectively. 
p-p38(Thr180/Tyr182), p-IκBα (s32/36), p-PTEN(S380), 
and Bim (C34C5) antibodies were purchased from Cell 
Signaling Technology. Flag (clone M2) antibody was from 
Sigma. Goat anti-mouse IgG-HRP, mouse anti-rabbit IgG-
HRP, and mouse anti-goat IgG-HRP, and all other primary 
antibodies were purchased from Santa Cruz. BAY11-7085, 




293 and 293T are human kidney epithelial cell 
lines. SavI, SavIII, P3HR1 and JiJoye are human B cell 
lines derived from EBV-positive Burkitt’s lymphoma 
patients. P3HR1 was derived from JiJoye but does not 
express LMP1 due to lacking the entire EBNA2 ORF in 
the viral genome [71]. The LCL line IB4 was derived from 
umbilical cord B-lymphocytes latently infected with EBV 
in vitro. CEM is a HTLV1-negative, EBV-negative T cell 
line derived from acute leukemia, and MT4 is a HTLV1-
transformed CD4+ T cell line derived from umbilical cord 
blood lymphocytes.  Epithelial cells are cultured with 
DMEM plus 10% FBS and antibiotics, and B and T cells 
are cultured with RPMI1640 medium plus 10% FBS and 
antibiotics. All cell culture supplies were purchased from 
Life Technologies.
Transfection
Lentiviral packing, preparation, infection, and 
selection of stable cells by puromycin were performed 
as detailed in our previous publication [31, 55]. LIMD1 
shRNA expression was induced by 1 µg/ml DOX. For 
other transfection of B cells, the Nucleofector kit for 
human B cells (Lonza) or the Gene Pulser Xcell system 
(Bio-Rad) was used. 293 and 293T cells were transfected 
with Effectene (Qiagen) or Fugene HD (Promega). 
Promoter-reporter assays
293 cells were transfected with expression plasmids 
as indicated together with LIMD1p-Luc2 (or its mutants) 
and Renilla as internal transfection control. Empty vector 
was used to equalize the total amounts of DNA in all 
transfections. Cells were collected 24 h after transfection. 
Luciferase activity was measured with equal amounts 
(10% of total for each sample) of protein lysates with 
the use of a Dual Luciferase Assay kit (Promega), on a 
multimode microplate reader (Turner Biosystems). Results 
are the mean ± standard error (SE) of duplicates for each 
sample. At least three consistent results were obtained 
from independent experiments and representative results 
are shown. The ability of the empty vector controls to 
activate the promoter constructs was set to 1.
Immunoprecipitation and immunoblotting
For endogenous protein interaction, 1 × 107 cells 
were used for each IP. For interaction between transiently 
expressed proteins, 293T cells in 60-mm dishes were 
collected 48 h after transfection. Cells were lysed with 
NP40 lysis buffer (150 mM NaCl, 1% NP-40, 50 mM 
Tris-pH 8.0, plus protease inhibitors), and cell lysates 
were subjected to immunoprecipitation with 1.5 µg 
indicated antibodies for overnight, and then incubated 
with 40 µl Protein A/G beads (Santa Cruz) for 1 h. After 
three washes, proteins on beads were denatured before 
separated by SDS-PAGE. Immunoblotting was carried out 
with indicated antibodies and signals were detected with 
an enhanced chemiluminescence (ECL) kit following the 
manufacturer’s protocol (Amersham Pharmacia Biotech).
Real-time quantitative PCR 
Quantitative PCR (qPCR) was performed with 
the use of SYBR Green (Applied Biosystems), on a 
CFX96TM Real-time PCR Detection System (Bio-Rad 
Laboratories, Inc.). All reactions were run in duplicates. 
Mean cycle threshold (Ct) values were normalized to 
18 s rRNA, yielding a normalized Ct (ΔCt). ΔΔCt
 value 
was calculated by subtracting respective control from the 
ΔCt, and expression level was then calculated by 2 raised 
to the power of respective –ΔΔCt
 value. The averages of 
2^(–ΔΔCt) in the control samples were set to 1 or 100%. 
Results are the average ± standard error (SE) of triplicates 
for each sample. Primers for real-time qPCR are as follows: 
LIMD1: F: 5′-TGGGGAACCTCTACCATGAC-3′ and 
R: 5′-CACAAAACACTTTGCCGTTG-3′; p62: F: 5'-TG 
CTAGGCCAGTGAAGGGAG-3' and R: 5'-CTTGTCTG 
TTGTGGGTAAAGCAAC-3'; IRF4: F: 5′-CGGGCAA 
GCAGGACTACAAC-3′ and R: 5′-CCTTTAAACAGT 
GCCCAAGCC-3′; Bcl6: F: 5′-CGCAACTCTGAAGA 
GCCACCTGCG-3′ and R: 5′-TTTGTGACGGAAATG 
CAGGTTA-3′. 18 s rRNA: F: 5′-GGCCCTGTAATTG 
GAATGAGTC-3′ and R: 5′-CCAAGATCCAACTACGA 
GCTT-3′.
Apoptosis assay
Apoptosis was assayed using flow cytometry as 
detailed in our previous publication [29], for Annex V 
binding (BD Biosciences, San Jose, CA). Caspase 3 
activity and apoptosis-related proteins including Bim 
expression were evaluated by Western blotting.
Chromosome immunoprecipitation (ChIP) 
ChIP was performed in 293 cells as described in our 
previous publication [55], with the use of ChIP-IT Express 
Enzymatic kit (Active Motif). qPCR was performed 
with the human LIMD1 promoter EICE primers: 5′- AA 
GGCTGCGGCAAGGGGCCG-3′ (forward) and 5′-CACC 
AGGCCTGACTCCTTGG-3′ (reverse), and the NFκB- 
binding site primers: 5′-TGCGCGCAGGCACAACG 
AG-3′ (forward) and 5′- CGTGTCACCCATGGCTGG-3′ 
(reverse).
Statistical analysis
Unpaired, two-tailed student t tests were executed 
using Graphpad Prism (version 5) to determine the 
differences between two data sets obtained from three 
independent experiments. p < 0.05 (*) and p < 0.01 
Oncotarget6295www.impactjournals.com/oncotarget
(**) were considered significant and p < 0.001 (***) was 
considered very significant. Data are expressed as mean 
± standard error (SE) of duplicate or triplicate samples, 
and representative results from at least three with similar 
results are shown.
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